Fundamental Analysis of NEOVACS(EPA:ALNEV) stock

Fundamental Rating

Overall ALNEV gets a fundamental rating of 2 out of 10. We evaluated ALNEV against 73 industry peers in the Biotechnology industry. Both the profitability and financial health of ALNEV have multiple concerns. ALNEV is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ALNEV has reported negative net income.

In the past year ALNEV has reported a negative cash flow from operations.

ALNEV had negative earnings in each of the past 5 years.

In the past 5 years ALNEV always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -16.63%, ALNEV is in the better half of the industry, outperforming 64.71% of the companies in the same industry.

ALNEV has a better Return On Equity (-17.90%) than 67.65% of its industry peers.

		Industry Rank	Sector Rank
ROA	-16.63%
ROE	-17.9%
ROIC	N/A

ROA(3y)-15.81%

ROA(5y)-38.36%

ROE(3y)-17.31%

ROE(5y)-74.96%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ALNEV's Gross Margin of 5.50% is in line compared to the rest of the industry. ALNEV outperforms 45.59% of its industry peers.

ALNEV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	5.5%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ALNEV does not have a ROIC to compare to the WACC, probably because it is not profitable.

ALNEV has more shares outstanding than it did 1 year ago.

ALNEV has more shares outstanding than it did 5 years ago.

ALNEV has a better debt/assets ratio than last year.

2.2 Solvency

ALNEV has an Altman-Z score of -2.94. This is a bad value and indicates that ALNEV is not financially healthy and even has some risk of bankruptcy.

The Altman-Z score of ALNEV (-2.94) is worse than 64.71% of its industry peers.

ALNEV has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.

With an excellent Debt to Equity ratio value of 0.01, ALNEV belongs to the best of the industry, outperforming 86.76% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF	N/A
Altman-Z	-2.94

ROIC/WACCN/A

WACC3.7%

2.3 Liquidity

ALNEV has a Current Ratio of 1.03. This is a normal value and indicates that ALNEV is financially healthy and should not expect problems in meeting its short term obligations.

ALNEV has a Current ratio of 1.03. This is in the lower half of the industry: ALNEV underperforms 75.00% of its industry peers.

ALNEV has a Quick Ratio of 1.03. This is a normal value and indicates that ALNEV is financially healthy and should not expect problems in meeting its short term obligations.

ALNEV has a Quick ratio of 1.03. This is in the lower half of the industry: ALNEV underperforms 67.65% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.03
Quick Ratio	1.03

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 99.82% over the past year.

ALNEV shows a strong growth in Revenue. In the last year, the Revenue has grown by 943.65%.

Measured over the past years, ALNEV shows a very strong growth in Revenue. The Revenue has been growing by 161.65% on average per year.

EPS 1Y (TTM)99.82%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%100%

Revenue 1Y (TTM)943.65%

Revenue growth 3Y161.65%

Revenue growth 5YN/A

Sales Q2Q%38732.43%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALNEV. In the last year negative earnings were reported.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ALNEV does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

NEOVACS

EPA:ALNEV (10/17/2024, 7:00:00 PM)

0.0002

0 (0%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap1.87K

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-16.63%
ROE	-17.9%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	5.5%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.01

Health

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	1.03
Quick Ratio	1.03
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)99.82%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next YN/A

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)943.65%

Revenue growth 3Y161.65%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

NEOVACS (ALNEV.PA)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens